Chemotherapy for Pancreatic Cancer / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 111-118, 2008.
Artigo
em Coreano
| WPRIM
| ID: wpr-186029
ABSTRACT
Chemotherapy is expected to play an important role in the treatment of pancreatic cancer because most of pancreatic cancers are being discovered at locally advanced or metastatic stages and recurrence rate is high even after the curative resection. Gemcitabine is a key agent for the first-line therapy of advanced pancreatic cancer. It can enhance the quality of life and prolong the survival of patients. Combination of erlotinib or capecitabine with gemcitabine showed a marginal survival benefit over single-agent gemcitabine. If patient's performance state is good, gemcitabine-based platinum combination therapy showed overall survival benefit compared with gemcitabine monothrapy. If the first-line palliative chemotherapy fails, 5-FU, capcitabine, or tegafur with or without combination can be used as the second-line agents. Adjuvant chemotherapy using 5-FU or gemcitabine after curative resection has overall survival benefit. However, neoadjuvant chemotherapy has not been proven to be effective in the treatment of pancreatic cancer.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Pancreáticas
/
Quinazolinas
/
Quimioterapia Adjuvante
/
Desoxicitidina
/
Inibidores de Proteínas Quinases
/
Fluoruracila
/
Antimetabólitos
/
Antimetabólitos Antineoplásicos
Limite:
Humanos
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS